Needham Keeps Buy Rating on Geron (GERN) After Q2 Results

Geron Corporation (NASDAQ:GERN) is one of the 10 Best Penny Stocks to Buy for the Next 5 Years. On August 6, Needham reiterated its Buy rating for Geron Corporation (NASDAQ:GERN) with a price target of $5. This decision came after the company reported results for the second quarter of 2025.

The firm highlighted the strong performance of Geron Corporation’s (NASDAQ:GERN) RYTELO  in the second quarter, which surpassed expectations in sales with a notable quarter-over-quarter growth.

In the second quarter of 2025, RYTELO net product revenue reached $49 million, rising by 24% compared to the first quarter. The demand for RYTELO also increased by 17% in the second quarter. This compares to just 1% increase in demand in the first quarter. This growth was fueled by new patient starts.

Another positive development was the recent appointment of Harout Semerjian, an experienced commercial hematology and oncology leader, as the new CEO of Geron Corporation (NASDAQ:GERN).

Geron Corporation (NASDAQ:GERN) is a commercial-stage biopharmaceutical company focused on developing therapies for patients with blood cancers.

While we acknowledge the potential of GERN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 11 Best Revenue Growth Stocks to Buy Now and 11 Best Under-the-Radar Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.